Oncology

Latest News

Future validation studies with a larger sample size are warranted to ensure the technique will be useful in a clinical setting. | Image credit: Artur Wnorowski - stock.adobe.com
Novel, Noninvasive Skin Cancer Detection Method Shows Promise

May 18th 2025

The tool could make it easier for clinicians to rule out melanoma without the need for excision.

FDA Approved | Image credit: chrisdorney – stock.adobe.com
Teliso-V Approved to Treat Advanced NSCLC With High c-Met Protein Overexpression

May 14th 2025

While CTCs were identified regardless of disease stage, the current study identified large variations in the presence of CTCs between nonmetastatic and metastatic disease | Image Credit: Innovative Creation - stock.adobe.com
Flow Cytometry Can Reliably Identify CTC in Melanoma

May 14th 2025

Jack & Sheryl Morris Cancer Center | Image credit: RWJBarnabas Health
New Jersey’s First Freestanding Cancer Hospital Opens in New Brunswick

May 14th 2025

At 3 months, hospitalizations among patients enrolled in RSM were 19% lower vs historical controls. | Image Credit: Nuttapong punna - stock.adobe.com
Remote Symptom Monitoring Linked to Reduced Hospitalization Risk for Patients With Cancer

May 14th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

Positive OS for Bladder Cancer Combo, Biomarkers on Tap at ASCO GU 2025
February 11th 2025

Positive OS for Bladder Cancer Combo, Biomarkers on Tap at ASCO GU 2025

Mary Caffrey
Data on enfortumab vedotin plus pembrolizumab for advanced bladder cancer, along with updates on antibody-drug conjugates, biomarkers, and other cancer treatments, will be highlighted at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU).
Debra Patt, MD, PhD, MBA, MPH
February 10th 2025

The “Secret Sauce” in Oncology: The Partnership Between Clinicians and AI

Mary Caffrey Debra Patt, MD, PhD, MBA, MPH
“To error is human, and also to error is in machine learning,” said Debra Patt, MD, PhD, MBA, MPH.
Burning cigarette | Image Credit: nikkytok - stock.adobe.com
February 10th 2025

Pain Linked to Greater Cigarette, E-Cigarette, Cannabis Use Among Cancer Survivors

Brooke McCormick
These new data highlight the need for improved pain management among patients with cancer and survivors.
Terra Wonsettler, PharmD, MBA | Image credit: Evolent
February 7th 2025

Evolent’s Wonsettler Sees Outcomes-Based Reimbursement as “A Healthy Tool”

Terra Wonsettler, PharmD, MBA Interview by Mary Caffrey
Terra Wonsettler, PharmD, MBA, vice president of pharmacy for Evolent, discusses the recent HHS OIG report that stemmed from the 2021 FDA approval of aducanumab (Aduhelm) and use of the accelerated approval pathway.
Doctor showing patient lung x-ray. | Image credit: Dragana Gordic – stock.adobe.com
February 7th 2025

Study Finds Declining SCLC Incidence, but Stagnant Survival Rates

Hayden E. Klein
SEER data show that small cell lung cancer (SCLS) incidence has steadily declined due to reduced smoking rates, but survival outcomes have seen only minimal improvement, underscoring the need for more effective treatments.
AJMC
February 7th 2025

Hospitalization Patterns Among Older Patients With Cancer With and Without Dementia

Zhigang Xie, PhD, MPA Hanadi Y. Hamadi, PhD Elissa Barr, PhD Beomyoung Cho, PhD, MPH Shraddha Patel, MPH Young-Rock Hong, PhD, MPH
Dementia was more prevalent in older patients with some cancer types, and comorbid dementia in this population was associated with unplanned or unnecessary hospitalization.
Older man after skin cancer surgery with bandage on face | Image credit: steheap – stock.adobe.com
February 7th 2025

Keratinocyte Skin Cancer Surgery Considered Safe, Effective in Older Patients

Hayden E. Klein
A single-center study suggests the surgery is safe and effective even when tumors are large or located in high-risk areas.
Flatiron Health, Exact Sciences Announce Deal to Speed Evidence Generation With MRD Test
February 6th 2025

Flatiron Health, Exact Sciences Announce Deal to Speed Evidence Generation With MRD Test

AJMC Staff
The companies announced the deal in a statement February 5, 2025, noting that the first patient had enrolled in a prospective clinical study using the test to monitor cancer recurrence across multiple solid tumor types.
Clayton Irvine, PharmD, MBA, MS.
February 6th 2025

Addressing Cancer Treatment Costs With Patient-Provider Communication

Cameron Santoro Clayton Irvine, PharmD, MBA, MS
Clayton Irvine, PharmD, MBA, MS, senior manager of oncology care at Mayo Clinic, emphasizes the need for health care providers to balance quality patient care with rising costs by openly discussing financial implications with patients and educating themselves on cost-effective treatments.
Debra Patt, MD, PhD, MBA, MPH
February 6th 2025

Dr Debra Patt on Prior Authorization: Something Has to Give

Mary Caffrey Debra Patt, MD, PhD, MBA, MPH
Debra Patt, MD, PhD, MBA, MPH, warns that prior authorization barriers are delaying critical cancer treatments and urges a regulatory fix for Stark Law restrictions on mailing oral oncolytics.
AI concept of cancer vaccine | Image credit: radekcho - stock.adobe.com
February 5th 2025

Promising Cancer Vaccine Boosts Hope for Stage III and IV Kidney Cancer

Pearl Steinzor
All patients involved in the phase 1 trial of a personalized cancer vaccine for high-risk stage III/IV kidney cancer showed a successful anticancer immune response.
COA Offers “Prescription” for Tackling Rising Costs, Loss of Patient Access in Cancer Care and Beyond
February 5th 2025

COA Offers “Prescription” for Tackling Rising Costs, Loss of Patient Access in Cancer Care and Beyond

Mary Caffrey
The 5-part plan focuses on issues that have been calling cards for the Community Oncology Alliance (COA) in recent years, which gained traction in the last Congress and show up regularly on lists of the most pressing problems in health care.
Debra Patt, MD, PhD, MBA, MPH
February 4th 2025

Dr Debra Patt Pushes for PBM Reform and Physician Reimbursement Fixes

Mary Caffrey Debra Patt, MD, PhD, MBA, MPH
Debra Patt, MD, PhD, MBA, MPH, emphasizes advocacy for pharmacy benefit manager (PBM) reform, physician reimbursement, and sustainable policy solutions to improve access to community cancer care.
Older patient exercising | image credit: MAGIC - stock.adobe.com
February 4th 2025

New Findings Strengthen Case for Exercise Therapy in Cancer Care

Kyle Munz
A new meta-analysis adds to the body of literature promoting the benefits of exercise for patients with cancer.
Oscar B. Lahoud, MD, and Kasey Bond, MPH
February 4th 2025

Addressing Cancer Care Barriers Through Community Outreach and Support

Maggie L. Shaw Oscar B. Lahoud, MD Kasey Bond, MPH
February 4 is World Cancer Day, and in these interviews with our Strategic Alliance Partner, NYU Langone Health, we learn about the importance of forming strong relationships with the communities you are located in and with whom you work to optimize cancer-related outcomes.
Oncology Research | Image credit: iStock
January 30th 2025

Oncology R&D Will Follow Divergent Paths, Experts Say at JPM Event

Mary Caffrey
A panel discussion during the JPMorgan conference earlier this month examined where oncology drug development is headed, driven in part by advances in diagnostic testing.
FDA Approval | Image credit: wladimir1804 - stock.adobe.com
January 29th 2025

FDA Approves Companion Diagnostic for Tovorafenib in BRAF-Altered Pediatric Low-Grade Glioma

Ashling Wahner
Tovorafenib generated durable drug holiday responses in pediatric patients with BRAF-altered relapsed/refractory low-grade glioma.
Chelsee Jensen, PharmD, BCPS.
January 29th 2025

Optimizing Oncology Drug Use While Mitigating Shortages

Cameron Santoro Chelsee J. Jensen, PharmD, BCPS
Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist at Mayo Clinic, suggests that medical providers can reduce patient and system costs by optimizing the use of generics and biosimilars, which offer lower costs without compromising safety and efficacy.
Kirollos Hanna, PharmD
January 28th 2025

Balancing Longevity, Quality, and Cost in Oncology Care

Kyle Munz Kirollos Hanna, PharmD
Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, director of pharmacy at Minnesota Oncology, discusses how the prospect of patient longevity, amidst advancing therapeutics, factors into oncology care.
Female hands pointing at map | Image Credit: undrey - stock.adobe.com
January 27th 2025

Historical Redlining Increases Mortality Risk Among Young Patients With Cancer

Brooke McCormick
Young patients with cancer residing in historically redlined areas face a significantly higher risk of mortality, demonstrating that structural racism contributes to disparities in survival outcomes.
Edgardo S. Santos Castillero, MD, FACP, FASCO | Image credit: TOI
January 25th 2025

Zongertinib Offers “The Best Toxicity Profile I Have Ever Seen,” Santos Says

Edgardo S. Santos Castillero, MD, FACP, FASCO Interview by Mary Caffrey
Flatiron Health, DeepScribe Unveil Partnership to Provide Oncology-Specific Ambient AI
January 22nd 2025

Flatiron Health, DeepScribe Unveil Partnership to Provide Oncology-Specific Ambient AI

Mary Caffrey
DeepScribe's technology aims to free doctors to focus on the patient visit.
AJMC
January 20th 2025

Effects of Individualized Nurse-Led Care Plans on Olaparib Treatment Duration

Denise Tran, PharmD Haesuk Park, PhD Jordon Rabey, MS Seth Killion, BS S. Bobby Arelli, MD Elaine Murphy, BS Yoona Kim, PharmD, PhD
A nurse-led personalized care program conducted through a specialty pharmacy prolonged medication persistence among patients with cancer receiving olaparib.
The new guideline is the NCCN’s first patient resource on the topic of cancer genetics and hereditary cancer risk. | Image credit: Connect world - stock.adobe.com
January 16th 2025

NCCN Publishes Patient Guidance on Genetic Testing for Cancer Risk

Rose McNulty
A new resource from the National Comprehensive Cancer Network (NCCN) provides evidence-based guidance on assessing and testing for inherited genetic mutations linked with increased cancer risk.
Patient receiving lung cancer screening results | Image Credit: Nattakorn - stock.adobe.com
January 13th 2025

Lung Cancer Screening Facilities Least Accessible to American Indian/Alaska Native Patients, Rural Communities

Brooke McCormick
Some populations face significant disparities in accessing lung cancer screening facilities, with American Indian/Alaska Native (AI/AN)-majority and rural census tracts facing the greatest travel distances.
Child standing on scale | Image Credit: Protsenko Dmitriy - stock.adobe.com
January 13th 2025

Obesity at Cancer Diagnosis Linked to Worse Survival Outcomes in Pediatric Patients

Brooke McCormick
Pediatric patients considered obese at cancer diagnosis are linked to significantly worse survival outcomes, especially those with acute lymphoblastic leukemia and central nervous system tumors.
Houston, TX | Image credit: Kovacs – stock.adobe.com
January 7th 2025

Decisions and Precision in Value-Based Cancer Care

Hayden E. Klein
An Institute for Value-Based Medicine regional event in Houston, Texas, covered inconsistencies with the integration of precision medicine in oncology practices, the evolution of treatment for multiple myeloma, and more.
FDA approved. | Image Credit: Pawel - stock.adobe.com .jpeg
January 2nd 2025

FDA Approves First Subcutaneous Nivolumab Injection in Most Solid Tumors

Pearl Steinzor
FDA approves the first subcutaneous version of nivolumab, making PD-1 inhibitors available to new groups of patients.
gastric cancer | Image credit: Crystal light - stock.adobe.com
January 2nd 2025

FDA Approves Tislelizumab-jsgr as First-Line Therapy for HER2– Gastric Cancers

Skylar Jeremias
Tislelizumab-jsgr (Tevimbra) was approved in combination with chemotherapy for the treatment of unresectable or metastatic HER2-negative (HER–) gastric or gastroesophageal junction adenocarcinoma (G/GEJ) in adults whose tumors express PD-L1.
Highlights From ACCC Fall 2024
January 1st 2025

ICYMI: Highlights From ACCC Fall 2024

Pearl Steinzor
Top content from the Association of Cancer Care Centers (ACCC) fall conference included topics on patient participation, new cancer care programs, prior authorization processing, and more.
<12345678
...
185>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo